Clinical Trial

Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors

Study acronym: LIFE
Recruiting
View on ClinicalTrials.gov →
Summary
Evaluation of the relation between baseline fibroblast activation protein (FAP) expression based on Ga-FAPI uptake with patient outcome among NSCLC patients receiving immunotherapy for recurrent/metastatic disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-24.
Trial Details
NCT Number NCT06107608
Lead Sponsor Jules Bordet Institute
Conditions Non Small Cell Lung Cancer
Enrollment 58 participants
Start Date 2023-06-13
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-31